Hwoei Fen Soo Hoo

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Manish A. Shah, Kohei Shitara, Jaffer A. Ajani et al. · Nature Medicine · 2023 · 551 citations · Full text

Medicine, Oncology, Pharmacology +16

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2023 · 319 citations · Full text

Medicine, Oncology, Urology +17

Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.

Rui‐Hua Xu, Kohei Shitara, Jaffer A. Ajani et al. · Journal of Clinical Oncology · 2023 · 31 citations

Medicine, Oncology, Pharmacology +16

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting

Xavier Pivot, V.A. Shamrai, Giorgi Dzagnidze et al. · JAMA Oncology · 2022 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular pathology quality control in Southeast Asia: Results of a multiregional quality assurance study from MASTER KEY Asia

Hitomi Sumiyoshi Okuma, Hiroshi Yoshida, Yoshihisa Kobayashi et al. · Cancer Science · 2023 · 10 citations · Full text

Medicine, Oncology, Pathology +15